<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nonmyeloablative allogeneic stem cell transplantation (NMSCT) may destroy some <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> through a graft-versus-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> (GVT) effect, but <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> relapse and <z:mp ids='MP_0001799'>viral</z:mp> reactivation remain challenges for which immunizations may be helpful </plain></SENT>
<SENT sid="1" pm="."><plain>Dendritic cells (DC), particularly DC1 and ex vivo-cultured DC, induce antigen-specific immune responses following <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> and anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> immunizations </plain></SENT>
<SENT sid="2" pm="."><plain>DC2 may be tolerogenic </plain></SENT>
<SENT sid="3" pm="."><plain>We hypothesize that successful immunizations following NMSCT will require adequate numbers of functional DC1 or ex vivo-generated DC </plain></SENT>
<SENT sid="4" pm="."><plain>We determined the number, phenotype, and function of blood DC1 and DC2 and ex vivo-generated DC obtained from donor-recipient pairs before and up to 90 days after NMSCT </plain></SENT>
<SENT sid="5" pm="."><plain>Although the percentage and number of recipient blood Lin(-) HLA-DR(+) CD11c(+) DC1 following NMSCT (median 0.46%, IQR 0.33-0.52%) was lower than donor DC1 (median 0.94%, IQR 0.40-2.2%) this was not significant </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, the percentage and absolute number of blood Lin(-) HLA-DR(+) CD11c(-) CD123(+) DC2 was significantly decreased following the transplant (median 0.01% IQR 0.01-0.01% at day 60 compared with median 0.14%, IQR 0.10-0.38% for the donor before transplantation, p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>The yield (median 6.0%, IQR 5.5-8.5%) and allostimulatory function of ex vivo-generated DC did not differ significantly at any time point </plain></SENT>
<SENT sid="8" pm="."><plain>The donor chimerism of blood and cultured DC reflected that of the overall white blood cells </plain></SENT>
<SENT sid="9" pm="."><plain>Ex vivo-generated, donor DC loaded with cytomegalovirus (CMV) antigens were capable of stimulating a CMV-specific immune response in vitro within peripheral blood mononuclear cells of a patient following NMSCT </plain></SENT>
<SENT sid="10" pm="."><plain>We conclude that blood DC numbers may be diminished following NMSCT transplant, but that DC1 recovery exceeds DC2 and functional DC may be generated from peripheral blood progenitors at <z:hpo ids='HP_0000001'>all</z:hpo> time points suggesting a possible use in immunization strategies </plain></SENT>
</text></document>